



Model List of Essential Medicines



Amikacin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amoxicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)



Amoxicillin + clavulanic acid [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Acute sinusitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Acute otitis media](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Ampicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Azithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Trachoma](#) [Cholera](#) [Cholera \[children\]](#) [Paratyphoid fever](#) [Chlamydia trachomatis](#) [Typhoid fever](#) [Yaws](#) co-prescribed with [ceftriaxone](#) [Gonococcal infection](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime](#) [Gonococcal infection](#)

Aztreonam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Bedaquiline [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Benzathine benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

First choice

[Congenital syphilis \[children\]](#) [Syphilis](#)

Other indications

[Bacterial infection of unspecified site](#)

Benzylnicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Congenital syphilis \[children\]](#) [Syphilis](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Capreomycin [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Cefalexin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

[Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

[Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Cefazolin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

[Other specified prophylactic measures Other specified prophylactic measures](#)

Second choice

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Surgical site infection](#)

Cefepime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

Cefiderocol [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Cefixime [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

Cefotaxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Ceftaroline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)

Ceftazidime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)



Ceftriaxone [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Other specified pneumonia \(Hospital-acquired pneumonia\) Inflammatory and other diseases of prostate \(severe\) Bacterial meningitis Acute pyelonephritis \(severe\) Paratyphoid fever Gonococcal infection Typhoid fever Peritonitis \(mild-moderate\) Peritonitis \(severe\) Peritoneal abscess \(mild-moderate\) Peritoneal abscess \(severe\) Endophthalmitis Bacterial pneumonia \(Community-acquired pneumonia - severe\) Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [metronidazole Necrotising fasciitis](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\) Acute pyelonephritis \(mild to moderate\) Bacterial infection of joint Sepsis without septic shock Osteomyelitis or osteitis Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)



Cefuroxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)



Chloramphenicol [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Ciprofloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Second choice

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Clarithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

Clindamycin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

[Necrotising fasciitis](#)

Second choice

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Clofazimine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Leprosy](#)

Cloxacillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

[Sepsis without septic shock](#)

Other indications

[Bacterial infection of unspecified site](#)

Colistin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Cycloserine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Dapsone [General information](#)

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

[Leprosy](#)

Daptomycin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Delafloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Delamanid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Dicloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Doxycycline [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

First choice

[Cholera](#) [Chlamydia trachomatis](#)

Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Cholera \[children\]](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

Other indications

[Bacterial infection of unspecified site](#)

Eravacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

Erythromycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Ethambutol [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis Tuberculosis](#)

Ethambutol + isoniazid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethambutol + isoniazid + pyrazinamide + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethambutol + isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)

Ethionamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis](#)

Fifth generation cephalosporins [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Flomoxef [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

Flucloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Fosfomycin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Fourth generation cephalosporins [General information](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Gatifloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Gentamicin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock](#) co-prescribed with [amoxicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [ampicillin Peritonitis \(mild-moderate\)](#) co-prescribed with [ampicillin Peritonitis \(severe\)](#) co-prescribed with [ampicillin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ampicillin Peritoneal abscess \(severe\)](#) co-prescribed with [ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

Second choice

[Gonococcal infection](#) [Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

Imipenem + cilastatin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Imipenem + cilastatin + relebactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales](#) [Other specified other antibiotic resistant Enterobacterales](#) [Carbapenem-resistant Pseudomonas aeruginosa](#)

Isoniazid [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis](#) [Tuberculosis](#)

Isoniazid + pyrazinamide + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

[Tuberculosis](#)

Isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)

Isoniazid + rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)



Kanamycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Levofloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Linezolid [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Meropenem [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

[Neonatal meningitis Peritonitis \(severe\) Peritoneal abscess \(severe\) Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Meropenem + vaborbactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)



Met icillin [General information](#)

Section
Access group antibiotics
Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Metronidazole [General information](#)

Section
Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

First choice

[Trichomoniasis](#) [Intestinal infections due to Clostridioides difficile](#) [Necrotising fasciitis](#) co-prescribed with [cefazolin](#) [Other specified prophylactic measures](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(severe\)](#)

Second choice

co-prescribed with [ciprofloxacin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin](#) [Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Moxifloxacin [General information](#)

Section
Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)

Nafcillin [General information](#)

Section
Access group antibiotics
Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Nitrofurantoin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

[Infectious cystitis](#)

Ofloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Omadacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Oxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

Therapeutic equivalent to [cloxacillin](#) for [Sepsis without septic shock](#)

Oxazolindinones [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

P-aminosalicylate sodium [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

P-aminosalicylic acid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Phenoxyethylpenicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Periapical abscess without sinus Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Piperacillin + tazobactam [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

[Neutropenia \(high-risk\) Other specified pneumonia \(Hospital-acquired pneumonia\) Peritonitis \(severe\) Peritoneal abscess \(severe\)](#) co-prescribed with [clindamycin Necrotising fasciitis](#)

Plazomicin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Polymyxin B (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)

Polymyxins [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Pretomanid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Procaine benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

[Congenital syphilis \[children\]](#)

Second choice

[Syphilis](#)

Protionamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

Therapeutic equivalent to [ethionamide](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Pyrazinamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

Rifabutin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

[Tuberculosis](#)

Rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

[Tuberculosis Other specified tuberculosis](#)

Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

[Leprosy](#)

Rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

Indications

[Tuberculosis Latent tuberculosis](#)

Spectinomycin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)

Streptomycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Sulfamethoxazole + trimethoprim [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

First choice

[Infectious cystitis](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

Tedizolid [General information](#)

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)

Terizidone [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > capsule: 250 mg

Indications

Therapeutic equivalent to [cycloserine](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Tetracycline [General information](#)

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)



Tigecycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)



Trimethoprim [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

First choice

[Infectious cystitis](#)



Vancomycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

[Necrotising fasciitis](#) co-prescribed with [ceftazidime Endophthalmitis](#) co-prescribed with [ceftriaxone Endophthalmitis](#)

Second choice

[Intestinal infections due to Clostridioides difficile Neutropenia \(high-risk\)](#)

Other indications

[Methicillin resistant Staphylococcus aureus](#)